Medical/Pharmaceuticals

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

TAMPA, Fla., April 2, 2024 /PRNewswire/ -- Concept Medical has been granted 'IDE Approval' from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, to initiate a clinical study for the treatment of stenotic lesions of Arteriovenous Fis...

2024-04-02 17:33 2114

Gushengtang Releases 2023 Annual Results: Sustained Growth with Robust Profit Increase

GUANGZHOU, China, April 2, 2024 /PRNewswire/ -- On March 27th, Gushengtang announced its financial results for 2023. During the year, the company's revenue reached2.323 billion yuan, marking a 43% year-over-year increase; the adjusted net profit was305 million yuan, increased by 53.6% compared to...

2024-04-02 16:49 2853

European Wellness Shines at AMWC 2024 in Monaco, with Prof. Dr Mike Chan and Prof. Dr Roni Moya as Faculty's Stem Cells Speakers

MONTE CARLO, Monaco, April 2, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), a global pioneer in biotechnology and bioregenerative medicine, is pleased to announce its extraordinary participation in the 22nd Aesthetic & Anti-Ageing Medicine World Congress (AMWC) 2024, which w...

2024-04-02 14:16 1634

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,...

2024-04-02 13:00 1865

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

HONG KONG and SHANGHAI, April 2, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended31 December 2023 (the "Reporting Period"). During the R...

2024-04-02 11:31 2973

23WELL, THE health supplement brand on the watch

LOS ANGELES, April 1, 2024 /PRNewswire/ -- Just earlier last month, the highly anticipated Natural Products Expo West 2024 concluded successfully inAnaheim, CA. As one of the world's largest leading health and nutrition exhibition, it hosted more than 65,000 registered attendees and 3,000+ exhibi...

2024-04-02 09:07 1598

Oncoclínicas&Co has revenues of R$6 billion and profit of R$313 million in 2023

Increase in the number of patients treated and gains in operational efficiency explain record results SÃO PAULO, April 2, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3) – the largest group dedicated to cancer treatment inLatin America – reported a 35.1% growth in its gross revenue in 2023, tot...

2024-04-02 00:38 1597

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of apaper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery. Together with a joint research group including investigators at theUniversity of Tokyo and the University of Brit...

2024-04-01 21:00 1696

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunotherapy success, pioneering next-gen personalized treatment approaches, supported by the AI-powered Lunit SCOPE suite SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

2024-04-01 21:00 1528

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk – a critical characterization step in the candidate dev...

2024-04-01 20:00 1954

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

~Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS inJapan and Asia~ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today ...

2024-04-01 14:30 1336

IMM CAREHUB - REDEFINING HEALTHY AGEING AND GERIATRIC REHABILITATION IN ASIA

KUALA LUMPUR, Malaysia, April 1, 2024 /PRNewswire/ --IMM Carehub, a pioneer in preventive care, healthy ageing, and geriatric rehabilitation, continues to make waves in the healthcare industry. AsMalaysia's First Lifestyle Rehab Centre for Seniors, IMM Carehub stands as a beacon of innovation and...

2024-04-01 09:00 1327

OFFICIAL LAUNCH OF THE NATIONAL UNIVERSITY SPINE INSTITUTE (NUSI): LEADING SPINE CARE INTO THE FUTURE

Public symposium by NUSI marks the end of a series of spine-related events that provide doctors with platform for professional development and networking SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under th...

2024-03-30 11:00 2417

CAIR-HK AI & Robotics Forum for Healthcare: Spotlight Interdisciplinary Integration of AI and Medicine

HONG KONG, March 29, 2024 /PRNewswire/ -- In this data-driven era, artificial intelligence and robotics technologies are rapidly reshaping people's lifestyles, with their profound impact in the field of medicine and healthcare becoming increasingly evident. From image-assisted diagnosis to intell...

2024-03-29 23:00 3184

Baird Medical Granted New Class III Certificate by China's NMPA for Ceramic Thyroid Ablation Needle

FRISCO, Texas, March 29, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced it has been granted a new Class III certificate by the National ...

2024-03-29 21:37 2231

Aohua receives Endoscopy Award at Healthcare Asia Medtech Awards 2024

SINGAPORE, March 29, 2024 /PRNewswire/ -- At the most recent Healthcare Asia Medtech Awards 2024, Aohua Endoscopy, a medical equipment manufacturer, won the Endoscopy Product Innovation Award for creating the Aohua4K AQ-300 video endoscopy system, which provides a better endoscopic diagnosis and ...

2024-03-29 21:00 3378

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...

2024-03-29 21:00 2336

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

SAN FRANCISCO, March 29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their cor...

2024-03-29 20:40 1841

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that th...

2024-03-29 20:00 1497

IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma

SHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced thatChina National Medical Products Administratio...

2024-03-29 17:20 1338
1 ... 6789101112 ... 576